RIGEL PHARMACEUTICALS INC— Sankey Diagram

Annual mode · period ending 2026-03-31 · SEC EDGAR

FY2026 - Q4(Jan 26 · Feb 26 · Mar 26)
Total Assets
$505M
↑+186.8% +$329Mvs FY2025
Total Liabilities
$105M
↓-33.5% -$53Mvs FY2025
Equity
$400M
↑+2053.8% +$381Mvs FY2025
Cash
$24M
↓-46.6% -$21Mvs FY2025
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
Reconciled values per the annual mode pipeline. Compare against SEC EDGAR filings.
Line itemFY2026FY2025
Total Assets$505M$176M
Current Assets$234M$147M
Cash$24M$46M
ST Investments$122M$31M
Receivables$50M$42M
Inventory$12M$5M
Other Current$26M$23M
Non-Current Assets$271M$29M
PPE$0$76K
Goodwill$0$0
Intangibles$24M$27M
Investments$0$0
Other Non-Current$246M$3M
Total Liab+Eq$505M$176M
Current Liab.$89M$67M
Accounts Payable$4M$4M
Short-Term Debt$0$0
Deferred Revenue$0$1M
Other CL$85M$61M
Non-Current Liab.$15M$91M
Long-Term Debt$45M$60M
Other LT Liab.$0$31M
Equity$400M$19M
Retained Earnings$1.01B$1.38B
Other Equity$0$0

QuarterCharts · SEC EDGAR data · RIGL · Comparing FY2026 vs FY2025